Annual industry ranking and forecast
Research & Development
Vaccines move up the agenda, COVID-19 continues to grow as a new drug development field, and novel modalities boost the overall pharma R&D pipeline.
An increasing number of sophisticated tools are on offer to address new therapeutic challenges and remaining unmet needs.
Global research and development for preventative vaccines and therapeutics to treat COVID-19 have progressed at a rapid pace. Still, key issues remain and to the dampen the effects of virus in 2022, even greater collaboration is needed.
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Pfizer's Prevnar 20 and Merck's Vaxneuvance are launching simultaneously and are expected to help drive vaccines growth for both big pharmas.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.